Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

133.06USD
10:54am EDT
Change (% chg)

$-2.16 (-1.60%)
Prev Close
$135.22
Open
$133.34
Day's High
$134.22
Day's Low
$133.03
Volume
428,193
Avg. Vol
1,876,571
52-wk High
$137.07
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

J&J says received subpoena in June from U.S. attorney's office
Thursday, 3 Aug 2017 05:32pm EDT 

Aug 3 (Reuters) - Johnson & Johnson -:J&J - in June 2017, co received a subpoena from the united states attorney's office for the district of Massachusetts‍​ - sec filing.J&J - June subpoena seeks information regarding practices related to sterilization of depuy synthes spinal implants at three hospitals in boston.J&J - June subpoena also seeks information regarding interactions of company employees with physicians at 3 boston hospitals.J&J - expects restructuring actions in medical devices segment will result eliminations of about 4 to 6 percent of segment’s global workforce over next 18 months‍​.J&J says about 2,100 positions have been eliminated of which 1,650 received separation payments since the restructuring announcement.  Full Article

Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine
Monday, 24 Jul 2017 04:00am EDT 

July 24 (Reuters) - J&J :Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine.Phase 1/2a approach study, HIV-1 antibody response observed in all healthy volunteers.Positive clinical, preclinical results inform selection of lead mosaic HIV vaccine regimen for further evaluation in phase 2b proof-of-concept study.J&J says should study move forward, Janssen and its global partners anticipate initiating this investigation in southern African countries in late 2017 or early 2018.  Full Article

EU Medicines Agency recommends approval J&J unit's Symtuza drug for HIV
Friday, 21 Jul 2017 07:26am EDT 

July 21 (Reuters) - EU Medicines Agency::EU Medicines Agency recommends approval of Johnson & Johnson unit Janssen-Cilag International N.V. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Symtuza) drug for HIV.  Full Article

Johnson & Johnson Q2 earnings per share $1.40
Tuesday, 18 Jul 2017 06:40am EDT 

July 18 (Reuters) - Johnson & Johnson ::Johnson & Johnson reports 2017 second-quarter results:.Q2 earnings per share $1.40.Q2 sales $18.8 billion versus I/B/E/S view $18.95 billion.Q2 earnings per share view $1.80 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $7.12 to $7.22.Q2 adjusted non-gaap earnings per share $1.83 excluding items.Sees FY 2017 sales $75.8 billion to $76.1 billion.J&J - ‍full-year adjusted EPS guidance increased to a range of $7.12 to $7.22​.J&J says worldwide consumer sales of $3.5 billion for Q2 2017 represented an increase of 1.7% versus prior year.J&J - ‍worldwide medical devices sales of $6.7 billion for Q2 2017 represented an increase of 4.9% versus prior year​.J&J says worldwide pharmaceutical sales of $8.6 billion for Q2 2017 represented a decrease of 0.2% versus prior year.J&J - excluding items, ‍on operational basis, Q2 worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%​.FY 2017 earnings per share view $7.10 -- Thomson Reuters I/B/E/S.J&J qtrly worldwide invokana/invokamet sales $‍​295 million versus $284 million in Q1.J&J - qtrly worldwide velcade sales $ ‍​290 million versus $280 million in Q1 2017.FY 2017 revenue view $75.68 billion -- Thomson Reuters I/B/E/S.J&J - ‍second-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.4 billion​.Q2 worldwide remicade sales $‍1,530​ million versus $1,672 million in Q1 2017.  Full Article

J&J sets quarterly cash dividend of $0.84 per share
Monday, 17 Jul 2017 10:33am EDT 

July 17 (Reuters) - J&J ::Sets quarterly cash dividend of $0.84 per share.  Full Article

Janssen announces FDA approval of Tremfya
Thursday, 13 Jul 2017 04:10pm EDT 

July 13 (Reuters) - Johnson & Johnson :Janssen announces U.S. FDA approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis.Janssen says Tremfya demonstrated superior results in skin clearance compared with Humira in head-to-head analyses at weeks 16, 24 and 48.Janssen- ‍seven out of ten patients receiving Tremfya achieved at least 90 percent improvement in skin clearance at week 16​.Janssen says applications seeking approval in European union, Japan and other countries are currently under review.  Full Article

Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option
Thursday, 6 Jul 2017 06:30pm EDT 

July 6 (Reuters) - Capricor Therapeutics Inc ::Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision.Capricor therapeutics retains full rights to cap-1002 as janssen biotech, inc. Decides not to exercise option.Capricor therapeutics inc-in connection with decision, collaboration agreement, license option entered into between co and janssen terminated.Capricor therapeutics inc-no payments between capricor and janssen are required to be made in relation to decision.Capricor therapeutics-co to have fully paid-up non-exclusive license under patents controlled by janssen utilized in production of clinical trial materials.Capricor therapeutics-to have non-exclusive license to publish, disclose, use information of janssen utilized in production of clinical trial materials.  Full Article

Depuy Synthes announces U.S. Launch of Viper and Expedium Fenestrated Screw Systems
Thursday, 29 Jun 2017 10:30am EDT 

June 29 (Reuters) - Depuy Synthes::Depuy synthes - announces U.S. Launch of Viper and Expedium Fenestrated screw systems.  Full Article

FDA grants priority review of Xarelto SNDA to reduce risk of recurrent VTE
Wednesday, 28 Jun 2017 08:30am EDT 

June 28 (Reuters) - Janssen::U.S. FDA grants priority review of Xarelto® (rivaroxaban) SNDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism (VTE).Janssen - ‍U.S. Food and Drug Administration accepted for priority review a supplemental new drug application (SNDA) for Xarelto (rivaroxaban)​.Janssen - ‍SNDA is to include 10 mg once-daily dose for reducing risk of VTE after atleast 6 months of standard anticoagulant therapy​‍​​.  Full Article

Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
Friday, 16 Jun 2017 01:06pm EDT 

June 16 (Reuters) - Genmab A/S :Genmab announces u.s. fda approval of darzalex(daratumumab) in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.Genmab - will receive milestone payments totaling $25 million from Janssen in connection with approval & first commercial sale of darzalex under newly expanded label.Genmab - approval and related milestones do not impact financial guidance issued by Genmab on May 10, 2017.  Full Article

Photo

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.